160 related articles for article (PubMed ID: 25271729)
1. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
de Wit D; van Erp NP; den Hartigh J; Wolterbeek R; den Hollander-van Deursen M; Labots M; Guchelaar HJ; Verheul HM; Gelderblom H
Ther Drug Monit; 2015 Jun; 37(3):331-8. PubMed ID: 25271729
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
Verheijen RB; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2017 Sep; 56(9):987-997. PubMed ID: 28185218
[TBL] [Abstract][Full Text] [Related]
4. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
5. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study.
Engels FK; Loos WJ; van der Bol JM; de Bruijn P; Mathijssen RH; Verweij J; Mathot RA
Clin Cancer Res; 2011 Jan; 17(2):353-62. PubMed ID: 21224369
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
[TBL] [Abstract][Full Text] [Related]
9. Dried blood spot analysis for therapeutic drug monitoring of pazopanib.
de Wit D; den Hartigh J; Gelderblom H; Qian Y; den Hollander M; Verheul H; Guchelaar HJ; van Erp NP
J Clin Pharmacol; 2015 Dec; 55(12):1344-50. PubMed ID: 26032288
[TBL] [Abstract][Full Text] [Related]
10. Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients.
Groenland SL; van Eerden RAG; Verheijen RB; de Vries N; Thijssen B; Rosing H; Beijnen JH; Koolen SLW; Mathijssen RHJ; Huitema ADR; Steeghs N;
Clin Pharmacokinet; 2020 Jul; 59(7):941-948. PubMed ID: 32020530
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).
Lubberman FJE; Gelderblom H; Hamberg P; Vervenne WL; Mulder SF; Jansman FGA; Colbers A; van der Graaf WTA; Burger DM; Luelmo S; Moes DJAR; van Herpen CML; van Erp NP
Clin Pharmacol Ther; 2019 Nov; 106(5):1076-1082. PubMed ID: 31125423
[TBL] [Abstract][Full Text] [Related]
12. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
Tanaka H; Hiraga H; Takekuma Y; Harabayashi T; Nagamori S; Endo M; Sugawara M
Biol Pharm Bull; 2020 May; 43(5):762-766. PubMed ID: 32115446
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
Ther Drug Monit; 2015 Apr; 37(2):172-9. PubMed ID: 25072946
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.
Bins S; Huitema ADR; Laven P; Bouazzaoui SE; Yu H; van Erp N; van Herpen C; Hamberg P; Gelderblom H; Steeghs N; Sleijfer S; van Schaik RHN; Mathijssen RHJ; Koolen SLW
Clin Pharmacokinet; 2019 May; 58(5):651-658. PubMed ID: 30367352
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
17. Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drug-Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy.
Srinivas NR
Am J Ther; 2019; 26(1):e54-e65. PubMed ID: 26808357
[TBL] [Abstract][Full Text] [Related]
18. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
Groenland SL; Katz D; Huitema ADR; Steeghs N
BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of pazopanib eye drops in healthy subjects and in subjects with neovascular age-related macular degeneration.
Singh R; Wurzelmann JI; Ye L; Henderson L; Hossain M; Trivedi T; Kelly DS
Retina; 2014 Sep; 34(9):1787-95. PubMed ID: 24896137
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Deng Y; Sychterz C; Suttle AB; Dar MM; Bershas D; Negash K; Qian Y; Chen EP; Gorycki PD; Ho MY
Xenobiotica; 2013 May; 43(5):443-53. PubMed ID: 23548165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
